National Institutes of Health Pathways to Prevention Workshop:
The Role of Opioids in the Treatment of Chronic Pain

September 29–30, 2014

Agenda

Monday, September 29, 2014

8:30 a.m. Welcome
Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse
National Institutes of Health

8:45 a.m. Opening Remarks
Story C. Landis, Ph.D.
Director
National Institute of Neurological Disorders and Stroke
National Institutes of Health

9:00 a.m. Charge to the Panel
David M. Murray, Ph.D.
Associate Director for Prevention
Director
Office of Disease Prevention
Division of Program Coordination, Planning, and Strategic Initiatives
Office of the Director
National Institutes of Health

9:10 a.m. Workshop Overview and Panel Activities
David B. Reuben, M.D.
Chief
Division of Geriatrics
Director
Multicampus Program in Geriatric Medicine and Gerontology
Professor of Medicine
Division of Geriatrics
David Geffen School of Medicine at the University of California, Los Angeles

9:20 a.m. Overview of Topic
David A. Thomas, Ph.D.
Deputy Director
Division of Clinical Neurosciences and Behavioral Research
National Institute on Drug Abuse
National Institutes of Health

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.
Monday, September 29, 2014 (continued)

9:40 a.m. **The Folly of Trying To Speak for the 100 Million Americans**  
*Myra Christopher, L.H.D. (Hon.)*  
Kathleen M. Foley Chair for Pain and Palliative Care  
Center for Practical Bioethics

10:00 a.m. **Clinician Perspective**  
*David J. Tauben, M.D.*  
Clinical Associate Professor  
Department of Medicine  
Chief (Interim)  
Division of Pain Medicine  
Medical Director  
Center for Pain Relief  
University of Washington

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:20 a.m. | Evidence-based Practice Center I: Overview of Systematic Review Methodology and What Is the Long-Term Effectiveness of Opioids?  
*Roger Chou, M.D., FACP*  
Director  
Pacific Northwest Evidence-based Practice Center  
Professor of Medicine  
Department of Medical Informatics & Clinical Epidemiology  
Oregon Health & Science University |
| 10:50 a.m. | What Is The Long-Term Effectiveness of Opioids: Interpretation of Evidence  
*Jane C. Ballantyne, M.D.*  
Professor, Retired  
Department of Anesthesiology and Pain Medicine  
University of Washington |
| 11:10 a.m. | Understanding the Data: Efficacy, Effectiveness, and Generalizability  
*Russell K. Portenoy, M.D.*  
Chief Medical Officer  
Metropolitan Jewish Health System (MHJS) Hospice and Palliative Care  
Director  
MJHS Institute for Innovation in Palliative Care  
Professor of Neurology  
Albert Einstein College of Medicine |
| 11:30 a.m. | Break |

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.
Monday, September 29, 2014 (continued)

11:50 a.m. Predicting Individual Differences in Opioid Analgesic Effectiveness
Stephen Bruehl, Ph.D.
Professor
Department of Anesthesiology
Vanderbilt University School of Medicine

12:10 p.m. Are Opioids Preferentially Effective in Treating Different Underlying Mechanisms of Chronic Pain?
Daniel J. Clauw, M.D.
Professor of Anesthesiology, Medicine and Psychiatry
Director
Chronic Pain and Fatigue Research Center
University of Michigan Medical Center

12:30 p.m. Lunch (to be provided at the expense of the attendee)

1:30 p.m. Discussion

II. What are the safety and harms of opioids in patients with chronic pain?

2:20 p.m. Evidence-based Practice Center II: What Are the Safety and Harms of Opioids in Patients With Chronic Pain?
Judith Turner, Ph.D.
Professor
Department of Psychiatry and Behavioral Sciences
University of Washington

2:40 p.m. Adverse Drug Reactions With Opioid Analgesic Use in Older Adults
Joseph T. Hanlon, Pharm.D., M.S.
Professor
Division of Geriatrics/Gerontology
Department of Medicine
University of Pittsburgh School of Medicine

3:00 p.m. Prescription Opioids and Substance Use Disorder
Edward C. Covington, M.D.
Director
Neurological Center for Pain
Cleveland Clinic

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.
Monday, September 29, 2014 (continued)

3:20 p.m.  **Risks of Opioid Therapy**  
*Nathaniel P. Katz, M.D., M.S.*  
President and Chief Executive Officer  
Analgesic Solutions  
Adjunct Assistant Professor of Anesthesia  
Tufts University School of Medicine

3:40 p.m.  **Public Health Impact**  
*Jane C. Maxwell, Ph.D.*  
Senior Research Scientist  
Addiction Research Institute  
University of Texas at Austin School of Social Work

4:00 p.m.  **Discussion**

5:00 p.m.  **Adjourn**

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.
## III. What are the effects of different opioid management strategies?

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 8:30 a.m.| **Evidence-based Practice Center Presentation III: What Are the Effects of Different Opioid Management Strategies?**  
*Roger Chou, M.D., FACP*  
Director  
Pacific Northwest Evidence-based Practice Center  
Professor of Medicine  
Department of Medical Informatics & Clinical Epidemiology  
Oregon Health & Science University |
| 8:50 a.m.| **Selected Strategies To Optimize Opioid Therapy and Decrease Risk of Abuse: State of the Evidence**  
*Ricardo A. Cruciani, M.D., Ph.D.*  
Director  
Center for Comprehensive Pain Management and Palliative Care  
Capital Institute for Neuroscience  
Capital Health Medical Center |
| 9:10 a.m.| **Effectiveness of Treatment Strategies for Managing Patients With Addiction to Prescription Opioids on Outcomes Related to Addiction, Abuse, Misuse, Pain, Function, and Quality of Life**  
*Steven D. Passik, Ph.D.*  
Vice President  
Clinical Research and Advocacy  
Millennium Research Institute  
Millennium Laboratories |
| 9:30 a.m.| **Impact of Pharmacokinetics and Pharmacodynamics: Relevance to Abuse and Addiction and Risks in Treatment**  
*Sharon Walsh, Ph.D.*  
Professor of Behavioral Sciences, Psychiatry, Pharmacology, and Pharmaceutical Science  
Director  
Center on Drug and Alcohol Research  
University of Kentucky College of Medicine |
| 9:50 a.m.| **Discussion** |

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td><strong>Evidence-based Practice Center IV: What Is the Effectiveness of Risk Mitigation Strategies for Opioid Treatment?</strong>&lt;br&gt;&lt;br&gt;<strong>Judith Turner, Ph.D.</strong>&lt;br&gt;Professor&lt;br&gt;Department of Psychiatry and Behavioral Sciences&lt;br&gt;University of Washington</td>
<td></td>
</tr>
<tr>
<td>10:50 a.m.</td>
<td><strong>Risk Mitigation by Way of Naloxone</strong>&lt;br&gt;&lt;br&gt;<em>Phillip O. Coffin, M.D., M.I.A.</em>&lt;br&gt;Director of Substance Use Research&lt;br&gt;HIV Prevention Section&lt;br&gt;San Francisco Department of Public Health</td>
<td></td>
</tr>
<tr>
<td>11:10 a.m.</td>
<td><strong>Opioid Risk Mitigation and Adherence Monitoring in Practice</strong>&lt;br&gt;&lt;br&gt;<em>Erin E. Krebs, M.D., M.P.H.</em>&lt;br&gt;Core Investigator&lt;br&gt;Center for Chronic Disease Outcomes Research&lt;br&gt;Medical Director&lt;br&gt;Women Veterans Comprehensive Health Center&lt;br&gt;Minneapolis Veterans Administration&lt;br&gt;Associate Professor&lt;br&gt;Department of Medicine&lt;br&gt;University of Minnesota</td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td><strong>Prescription Opioid Misuse and Addiction: A National Priority</strong>&lt;br&gt;&lt;br&gt;<em>Wilson M. Compton, M.D., M.P.E.</em>&lt;br&gt;Deputy Director&lt;br&gt;National Institute on Drug Abuse&lt;br&gt;National Institutes of Health</td>
<td></td>
</tr>
<tr>
<td>11:50 a.m.</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, September 30, 2014 (continued)

12:30 p.m.  Break

12:50 p.m.  Roundtable Discussion on Opioids in the Real World
            Wendy B. Smith, Ph.D., M.A., BCB, Moderator
            Senior Scientific Advisor for Research Development and Outreach
            Office of Behavioral and Social Sciences Research
            Office of the Director
            National Institutes of Health

            Daniel J. Clauw, M.D., Panelist
            Professor of Anesthesiology, Medicine and Psychiatry
            Director
            Chronic Pain and Fatigue Research Center
            University of Michigan Medical Center

            Ricardo A. Cruciani, M.D., Ph.D., Panelist
            Director
            Center for Comprehensive Pain Management and Palliative Care
            Capital Institute for Neuroscience
            Capital Health Medical Center

            Tracy W. Gaudet, M.D., Panelist
            Director
            Office of Patient Centered Care and Cultural Transformation
            Veterans Health Administration
            U.S. Department of Veterans Affairs

1:30 p.m.  Workshop Wrap-Up/Next Steps

1:40 p.m.  Adjourn

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.